Published in BMC Gastroenterol on August 26, 2016
IL33-mediated ILC2 activation and neutrophil IL5 production in the lung response after severe trauma: A reverse translation study from a human cohort to a mouse trauma model. PLoS Med (2017) 0.76
Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease. Mediators Inflamm (2017) 0.75
IL-33 and the intestine: The good, the bad, and the inflammatory. Cytokine (2017) 0.75
The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front Immunol (2017) 0.75
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Inflammatory bowel disease. Annu Rev Immunol (2010) 7.10
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis (2010) 3.97
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis (2012) 3.89
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2013) 3.83
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis (2014) 3.22
Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem (2007) 3.11
European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis (2013) 3.01
Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut (2006) 3.00
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol (2009) 2.27
Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A (2010) 2.22
Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol (2009) 2.16
Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis. Aliment Pharmacol Ther (2015) 2.06
Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut (2012) 1.97
Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis (2008) 1.69
Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.65
IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis (2010) 1.62
Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol (2000) 1.56
Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol Psychiatry (2009) 1.51
Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol (2013) 1.42
Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol (2009) 1.35
New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol (2013) 1.25
IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm Bowel Dis (2012) 1.19
Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis (2009) 1.18
Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol (2009) 1.15
Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis (2008) 1.04
Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut (2001) 1.04
Soluble ST2: a new and promising activity marker in ulcerative colitis. World J Gastroenterol (2011) 0.91
IL-33 and soluble ST2 levels as novel predictors for remission and progression of carotid plaque in early rheumatoid arthritis: A prospective study. Semin Arthritis Rheum (2015) 0.91
Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J (2014) 0.90
The valuable role of endoscopy in inflammatory bowel disease. Diagn Ther Endosc (2012) 0.89
High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling? Inflamm Bowel Dis (2015) 0.88
Fecal calprotectin: assessment of a rapid test. Scand J Clin Lab Invest (2008) 0.88
Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation. Inflamm Bowel Dis (2014) 0.88
Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs. World J Gastroenterol (2014) 0.86
Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol Immunother (2014) 0.85
Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU. Gastroenterol Hepatol (2013) 0.82
Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders. Expert Rev Gastroenterol Hepatol (2014) 0.81
Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis. J Gastroenterol Hepatol (2016) 0.80
Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33. Eur J Immunol (2015) 0.79
Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure. Int J Cardiol (2014) 0.78
Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin. J Crohns Colitis (2015) 0.78
Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol (2015) 0.77